Literature DB >> 24973197

Intracranial self-stimulation to evaluate abuse potential of drugs.

S Stevens Negus1, Laurence L Miller2.   

Abstract

Intracranial self-stimulation (ICSS) is a behavioral procedure in which operant responding is maintained by pulses of electrical brain stimulation. In research to study abuse-related drug effects, ICSS relies on electrode placements that target the medial forebrain bundle at the level of the lateral hypothalamus, and experimental sessions manipulate frequency or amplitude of stimulation to engender a wide range of baseline response rates or response probabilities. Under these conditions, drug-induced increases in low rates/probabilities of responding maintained by low frequencies/amplitudes of stimulation are interpreted as an abuse-related effect. Conversely, drug-induced decreases in high rates/probabilities of responding maintained by high frequencies/amplitudes of stimulation can be interpreted as an abuse-limiting effect. Overall abuse potential can be inferred from the relative expression of abuse-related and abuse-limiting effects. The sensitivity and selectivity of ICSS to detect abuse potential of many classes of abused drugs is similar to the sensitivity and selectivity of drug self-administration procedures. Moreover, similar to progressive-ratio drug self-administration procedures, ICSS data can be used to rank the relative abuse potential of different drugs. Strengths of ICSS in comparison with drug self-administration include 1) potential for simultaneous evaluation of both abuse-related and abuse-limiting effects, 2) flexibility for use with various routes of drug administration or drug vehicles, 3) utility for studies in drug-naive subjects as well as in subjects with controlled levels of prior drug exposure, and 4) utility for studies of drug time course. Taken together, these considerations suggest that ICSS can make significant contributions to the practice of abuse potential testing.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Year:  2014        PMID: 24973197      PMCID: PMC4081730          DOI: 10.1124/pr.112.007419

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  382 in total

Review 1.  Rate-dependent effects of drugs: a review of the literature.

Authors:  D J Sanger; D E Blackman
Journal:  Pharmacol Biochem Behav       Date:  1976-01       Impact factor: 3.533

2.  Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents.

Authors:  John F Cryan; Daniel Hoyer; Athina Markou
Journal:  Biol Psychiatry       Date:  2003-07-01       Impact factor: 13.382

3.  Tolerance to the anhedonic effects of lipopolysaccharide is associated with changes in syntaxin immunoreactivity in the nucleus accumbens.

Authors:  Alasdair M Barr; Cai Song; Ken Sawada; Clint E Young; William G Honer; Anthony G Phillips
Journal:  Int J Neuropsychopharmacol       Date:  2003-03       Impact factor: 5.176

4.  ELECTRICAL SELF-STIMULATION OF THE BRAIN IN MAN.

Authors:  R G HEATH
Journal:  Am J Psychiatry       Date:  1963-12       Impact factor: 18.112

Review 5.  Principles of assessment of abuse liability: US legal framework and regulatory environment.

Authors:  Beatriz A Rocha
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

6.  Behavioral effects of the delta-selective opioid agonist SNC80 and related compounds in rhesus monkeys.

Authors:  S S Negus; M B Gatch; N K Mello; X Zhang; K Rice
Journal:  J Pharmacol Exp Ther       Date:  1998-07       Impact factor: 4.030

7.  Diazepam and cocaine potentiate brain stimulation reward in C57BL/6J mice.

Authors:  Carolin J Straub; William A Carlezon; Uwe Rudolph
Journal:  Behav Brain Res       Date:  2009-08-27       Impact factor: 3.332

8.  Pentobarbital induces a naloxone-reversible decrease in mesolimbic self-stimulation threshold.

Authors:  T F Seeger; K R Carlson; J M Nazzaro
Journal:  Pharmacol Biochem Behav       Date:  1981-10       Impact factor: 3.533

9.  Hypothalamic neurotensin projections promote reward by enhancing glutamate transmission in the VTA.

Authors:  Kimberly A Kempadoo; Clara Tourino; Saemi L Cho; Francesco Magnani; Gina-Marie Leinninger; Garret D Stuber; Feng Zhang; Martin G Myers; Karl Deisseroth; Luis de Lecea; Antonello Bonci
Journal:  J Neurosci       Date:  2013-05-01       Impact factor: 6.167

10.  Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats.

Authors:  S Stevens Negus; Ember M Morrissey; Marisa Rosenberg; K Cheng; Kenner C Rice
Journal:  Psychopharmacology (Berl)       Date:  2010-01-26       Impact factor: 4.530

View more
  98 in total

1.  Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.

Authors:  Jason M Wiebelhaus; Travis W Grim; Robert A Owens; Matthew F Lazenka; Laura J Sim-Selley; Rehab A Abdullah; Micah J Niphakis; Robert E Vann; Benjamin F Cravatt; Jenny L Wiley; S Stevens Negus; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2014-11-14       Impact factor: 4.030

Review 2.  Determinants of opioid abuse potential: Insights using intracranial self-stimulation.

Authors:  S Stevens Negus; Megan J Moerke
Journal:  Peptides       Date:  2018-11-01       Impact factor: 3.750

3.  Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents.

Authors:  Ahmad A Altarifi; Bethany David; Karan H Muchhala; Bruce E Blough; Hamid Akbarali; S Stevens Negus
Journal:  J Psychopharmacol       Date:  2017-02-01       Impact factor: 4.153

4.  Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.

Authors:  Farhana Sakloth; Elizabeth Leggett; Megan J Moerke; E Andrew Townsend; Matthew L Banks; S Stevens Negus
Journal:  Exp Clin Psychopharmacol       Date:  2019-01-10       Impact factor: 3.157

5.  Amphetamine maintenance differentially modulates effects of cocaine, methylenedioxypyrovalerone (MDPV), and methamphetamine on intracranial self-stimulation and nucleus accumbens dopamine in rats.

Authors:  Amy R Johnson; Matthew L Banks; Dana E Selley; S Stevens Negus
Journal:  Neuropsychopharmacology       Date:  2018-04-19       Impact factor: 7.853

6.  Decoding the Structure of Abuse Potential for New Psychoactive Substances: Structure-Activity Relationships for Abuse-Related Effects of 4-Substituted Methcathinone Analogs.

Authors:  S Stevens Negus; Matthew L Banks
Journal:  Curr Top Behav Neurosci       Date:  2017

7.  Abuse liability assessment of an e-cigarette refill liquid using intracranial self-stimulation and self-administration models in rats.

Authors:  M G LeSage; M Staley; P Muelken; J R Smethells; I Stepanov; R I Vogel; P R Pentel; A C Harris
Journal:  Drug Alcohol Depend       Date:  2016-09-01       Impact factor: 4.492

8.  Sex differences in abuse-related neurochemical and behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats.

Authors:  M F Lazenka; J A Suyama; C T Bauer; M L Banks; S S Negus
Journal:  Pharmacol Biochem Behav       Date:  2016-08-24       Impact factor: 3.533

Review 9.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

10.  Effects of Acute and Repeated Administration of Oxycodone and Naloxone-Precipitated Withdrawal on Intracranial Self-Stimulation in Rats.

Authors:  Jason M Wiebelhaus; D Matthew Walentiny; Patrick M Beardsley
Journal:  J Pharmacol Exp Ther       Date:  2015-10-21       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.